Pancoast tumor medical therapy

Jump to navigation Jump to search


Pancoast tumor Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pancoast tumor from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pancoast tumor medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pancoast tumor medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pancoast tumor medical therapy

CDC onPancoast tumor medical therapy

Pancoast tumor medical therapy in the news

Blogs on Pancoast tumor medical therapy

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Pancoast tumor medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]

Overveiw

The optimal management approach of Pancoast tumor depends on a series of characteristics, that include pre-treatment evaluation, location, and adequate staging. Common treatment options for management include radiation therapy alone, radiation therapy and surgery, concurrent chemotherapy with radiation therapy and surgery, surgery alone (for selected patients).

Management Approach

The optimal management approach of Pancoast tumor depends on a series of characteristics, that include pre-treatment evaluation, location, and adequate staging. Common treatment options for management include:[1][2][3][4][5]

The treatment of Pancoast tumor may differ to that of other types of non-small cell lung cancer due to its position and close proximity to vital structures (such as nerves and spine) which may make surgery difficult to be undertaken. As a result, and depending on the stage of the cancer, treatment may often involve radiation and chemotherapy given pre-operatively (neoadjuvant treatment) prior to surgery.

Medical Therapy

Chemotherapeutic regimens are based on platinum agents such as cisplatin, carboplatin, oxaliplatin, and satraplatin. Alternative regimens include paclitaxel, gemcitabine, or etoposide. Chemotherapeutic regimens are adjusted based on individual characteristics and body surface. The regimen adjustment according to tumor evolution has demonstrated longer survival rates, optimal symptom control, and higher quality of life.

Chemotherapeutic Regimens

Cisplatin Based Therapy

Agent Recommended regimen
Cisplatin 50 mg/m2 + vinorelbine 25 mg/m2 Cisplatin on days 1 and 8, vinorelbine on days 1, 8, 15, 22, and every 28 days to a total of 4 cycles
Cisplatin 100 mg/m2 + vinorelbine 30 mg/m2 Cisplatin on day 1, vinorelbine on days 1, 8, 15, 22, and every 28 days to a total of 4 cycles
Cisplatin 75-80 mg/m2 + vinorelbine 25-50 mg/m2 Cisplatin on day 1, vinorelbine on days 1, 8, and every 21 days to a total of 4 cycles
Cisplatin 80 mg/m2 + vinorelbine 4 mg/m2 Cisplatin on days 1, 22, 43, 64, then every 21 days to a total of 4 cycles, vinorelbine on days 1, 8, 15, 22, 29, every 2 weeks after day 43 until the completion of cisplatin treatment
Cisplatin 100 mg/m2 + etoposide 100 mg/m2 Cisplatin on day 1, etoposide through days 1 to 3 and every 28 days to a total of 4 cycles
Cisplatin 75 mg/m2 + gemcitabine 1250 mg/m2 Cisplatin on day 1, gemcitabine on days 1, 8, and every 21 days to a total of 4 cycles
Cisplatin 75 mg/m2 + docetaxel 75 mg/m2 Cisplatin on day 1, docetaxel on day 1 and every 21 days to a total of 4 cycles
Cisplatin 50 mg/m2 + pemetrexed 500 mg/m2 Cisplatin on day 1, pemetrexed on days 1 and every 21 days to a total of 4 cycles

Alternative Regimen

Paclitaxel 200 mg/m2 on day 1 + carboplatin area under the concentration (AUC) 6 on day 1 and then every 21 days.[7]

Chemotherapy with Radiation Therapy Regimens

Chemotherapy plus Radiation Therapy

The list below show the options for concomitant chemotherapy plus radiation therapy based on the 2014 NCCN lung cancer guidelines.[7]

Chemotherapy Followed by Radiation Therapy

The list below show the options for chemotherapy followed by radiation therapy based on the 2014 NCCN lung cancer guidelines.[7]

Chemotherapy plus Radiation Therapy, Followed by Chemotherapy

The list below show the options for concomitant chemotherapy plus radiation therapy followed by chemotherapy based on the 2014 NCCN lung cancer guidelines.[7]

Radiation therapy can be applied to any stage of non-small cell lung cancer. In general, radiation therapy is recommended as palliative care treatment among patients who develop an advanced stage of non-small cell lung cancer or symptomatic patients with local involvement (pain, vocal cord paralysis, and hemoptysis). Curative radiation therapy may be indicated in patients who are not suitable for surgery with early-stage non-small cell lung cancer. The main goal of radiation therapy for non-small cell lung cancer is maximum tumor control with minimal tissue toxicity. The two main types of radiation therapy for non-small cell lung cancer are external beam radiation therapy (thoracic radiotherapy), and brachytherapy (internal radiation therapy).

Radiation Therapy

Radiation Therapy Regimens

  • Pancoast tumor, a subtype of lung cancer located at the lung apex. Shown below is a list of the different regimens radiation therapy for patients with Pancoast tumor. The list of regimens has been adapted from the 2014 NCCN lung cancer guidelines.[8][7]

Usual Dosages for Definitive Radiation Therapy

Administer fractions of 2 Gy over a period of 6 to 7.5 weeks to a total dose of 60 to 74 Gy

Neoadjuvant Radiation Therapy Regimen

Administer fractions of 1.8 to 2 Gy over a period of 5 weeks to a total dose of 45 to 50 Gy

Adjuvant Radiation Therapy Regimens

  • Negative surgical piece margins: Administer fractions of 1.8 to 2 Gy over a period of 5 to 6 weeks to a total dose of 40 to 54 Gy
  • Positive surgical piece margins: Administer fractions of 1.8 to 2 Gy over a period of 6 weeks to a total dose of 54 to 60 Gy
  • Extracapsular nodal extension: Administer fractions of 1.8 to 2 Gy over a period of 6 weeks to a total dose of 60 to 70 Gy
  • Residual tumor: Administer fractions of 2 Gy over a period of 6 to 7 weeks to a total dose of 54 to 60 Gy

Stereotactic Ablative Radiotherapy Usual Dosage

Palliative Radiation Therapy Regimens

Listed below are the recommended palliative radiation therapy regimens for patients with lung cancer according to the 2014 NCCN lung cancer guidelines.[7]

  • Administer fractions of 3 Gy over a period of 2 to 3 weeks to a total dose of 30 to 45 Gy
  • Administer fractions of 4 to 3 Gy over a period of 1 to 2 weeks to a total dose of 20 to 30 Gy
  • Administer fractions of 8 to 3 Gy over a period of 1 to 14 days to a total dose of 8 to 30 Gy
  • Administer fractions of 8.5 Gy over a period of 7 to 14 days to a total dose of 17 Gy
  • Administer fractions of 8 to 4 Gy over a period of 1 to 7 days to a total dose of 8 to 20 Gy
  • 10 fractions of 3 Gy each to a total of 30 Gy
  • 15 fractions of 2.5 Gy each to a total of 37.5 Gy
  • 5 fractions of 4 Gy each to a total of 20 Gy. Good option for patients with poor performance status.

References

  1. Davis GA, Knight SR (October 2008). "Pancoast tumors". Neurosurg. Clin. N. Am. 19 (4): 545–57, v–vi. doi:10.1016/j.nec.2008.07.002. PMID 19010280.
  2. Rosso L, Palleschi A, Mendogni P, Nosotti M (April 2016). "Video-assisted pulmonary lobectomy combined with transmanubrial approach for anterior Pancoast tumor resection: case report". J Cardiothorac Surg. 11 (1): 65. doi:10.1186/s13019-016-0446-7. PMC 4831106. PMID 27079507.
  3. Caronia FP, Fiorelli A, Ruffini E, Nicolosi M, Santini M, Lo Monte AI (September 2014). "A comparative analysis of Pancoast tumour resection performed via video-assisted thoracic surgery versus standard open approaches". Interact Cardiovasc Thorac Surg. 19 (3): 426–35. doi:10.1093/icvts/ivu115. PMID 25052071.
  4. Hubbard MO, Schroeder C, Linden PA (April 2011). "Routine use of staging thoracoscopy for pancoast tumors without overt radiographic chest wall invasion". Surg Laparosc Endosc Percutan Tech. 21 (2): 111–5. doi:10.1097/SLE.0b013e31821a3cb0. PMID 21471804.
  5. Tamura M, Hoda MA, Klepetko W (October 2009). "Current treatment paradigms of superior sulcus tumours". Eur J Cardiothorac Surg. 36 (4): 747–53. doi:10.1016/j.ejcts.2009.04.036. PMID 19699106.
  6. Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899
  7. 7.0 7.1 7.2 7.3 7.4 7.5 7.6 http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
  8. Pattern of use of radiotherapy for lung cancer: a descriptive study. BioMed Central. http://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-697#CR6 Accessed on March 1, 2016

Template:WH Template:WS